Scholar Rock Eyes 2026 Launch Amid Regulatory Push

Scholar Rock Holding ((SRRK)) has held its Q4 earnings call. Read on for the main highlights of the call.

Scholar Rock’s latest earnings call struck a cautiously optimistic tone, with management emphasizing regulatory traction, a deepening neuromuscular pipeline, and a visibly maturing commercial infrastructure. Investors were also reassured by expanded financing capacity, even as the company acknowledged lingering manufacturing and reimbursement risks that could affect the timing and shape of its first major launch.

Regulatory momentum toward U.S. resubmission and 2026 launch

Scholar Rock reiterated its plan to resubmit its biologics license application and is still aiming for a U.S. launch in 2026, contingent on regulatory green lights. The Food and Drug Administration has remained engaged, including a field team visit to Catalent’s Indiana facility, and intends to reinspect the site now that routine manufacturing restarted in late February, after which management says it is ready to move quickly.

European MAA review progressing

In Europe, the company’s marketing authorization application is moving through review with the European Medicines Agency, with management guiding to a mid‑2026 decision. A positive outcome would pave the way for a staggered rollout starting in Germany in the second half of 2026, positioning Europe as a follow‑on growth driver to an initial U.S. launch.

Pipeline progress — multiple programs advancing

The development engine remains active, with the Phase 2 OVAL study combining ipilimumab and epitogromab enrolling infants and toddlers under two years, including patients already treated with SMN‑targeted drugs. Beyond spinal muscular atrophy, the company is preparing to start the FORGE Phase 2 trial in facioscapulohumeral muscular dystrophy around mid‑2026 and is dosing healthy volunteers with SRK‑439, a high‑potency myostatin inhibitor expected to deliver top‑line Phase 1 data in the second half of 2026.

Commercial preparedness and community engagement

Ahead of potential approval, Scholar Rock has rolled out a U.S. commercial organization that is already calling on roughly 140 SMA treatment centers and about 2,600 prescribing physicians. The company has also built specialty pharmacy and home infusion networks, launched the “Life Takes Muscle” disease awareness campaign, and begun payer discussions across commercial and government channels to ease the path to adoption.

Strengthened balance sheet and financing flexibility

The balance sheet exited 2025 with $368.0 million in cash and equivalents, boosted by $60.4 million from warrant exercises in the fourth quarter alone. Management also locked in a debt facility of up to $550.0 million, providing staged access to capital before and after regulatory decisions and repaying an existing loan while preserving optionality for future draws.

Operating spend transparency and prioritization

Operating expenses stayed high as the company invested in late‑stage development and launch readiness, totaling $91.9 million in the fourth quarter and $384.6 million for 2025. Excluding non‑cash stock‑based compensation, which made up about one‑fifth of spending, core operating costs reached $72.5 million for the quarter and $309.0 million for the year, highlighting the scale of pre‑revenue investment.

Manufacturing compliance at Catalent created sole approvability issue

Management underscored that the prior complete response letter focused solely on manufacturing compliance at Catalent’s Indiana plant rather than on the drug’s clinical profile. Nevertheless, the timing and outcome of the anticipated FDA reinspection remain a key swing factor for the program, as resubmission and potential approval are effectively gated to that visit.

Supply chain concentration risk and reliance on third parties

The company acknowledged that its heavy reliance on a single Catalent fill‑finish facility has amplified regulatory and supply risk around launch. To mitigate that exposure, a second U.S. fill‑finish site is undergoing engineering runs, with a supplemental biologics filing planned for 2026, but execution risk persists until the backup facility is fully qualified and cleared.

High operating spend and funding needs ahead of revenue

With 2025 operating expenses roughly matching its year‑end cash balance even before including future launch costs, Scholar Rock signaled that sustained investment will be required before the business turns profitable. Management indicated that profitability is likely two to three years after launch, implying the company may tap additional financing sources or asset monetization to bridge the gap.

Potential payer access and launch uptake headwinds

While the company expects strong physician and patient interest, it warned that reimbursement dynamics could dampen the initial ramp, particularly among Medicaid plans and slower‑moving payers. A weight‑based dosing and pricing model could further complicate early negotiations, making market access strategy and contracting critical to converting demand into revenue.

Historical myostatin inhibitor efficacy risk for new indications

Management also acknowledged scientific risk in extending myostatin inhibition beyond SMA, noting that prior drugs in the class sometimes boosted muscle mass without translating into clear functional gains. The upcoming FORGE study in FSHD will track muscle volume as a primary endpoint alongside functional measures, but investors will watch closely to see whether structural changes deliver meaningful clinical benefit.

Forward‑looking guidance and milestones

Looking ahead, Scholar Rock is steering toward BLA resubmission and a potential U.S. approval and launch in 2026, with an EMA decision expected around mid‑2026 and a supplemental filing for a second fill‑finish site later that year. Key clinical catalysts include continued enrollment in OVAL, initiation of the roughly 60‑patient FORGE trial in mid‑2026, and first Phase 1 readout for SRK‑439 in the back half of 2026, all underpinned by expanded debt capacity and plans to further bolster the balance sheet.

Scholar Rock’s call painted the picture of a company on the cusp of its first commercial inflection, backed by active regulators, an expanding neuromuscular pipeline, and a significantly larger financial safety net. Execution risks around manufacturing compliance, payer access, and R&D productivity remain, but for now investors are being asked to weigh those uncertainties against a sizeable SMA market opportunity and a clear, if narrow, path to launch.